Eribulin
- TRADE NAME: Halaven (Eisai)
- INDICATIONS: Metastatic breast cancer in patients who have previously received at least two chemotherapeutic regimens (prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting); unresectable or metastatic liposarcoma in patients who have received a prior anthracycline-containing regimen
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Microtubule inhibitor
- HALF-LIFE: 40 hours
FDA APPROVAL DATE: 11/15/2010
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
No available data but caused embryo-fetal toxicity in animal studies
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of eribulin in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric